Fifth Third Bancorp Akebia Therapeutics, Inc. Transaction History
Fifth Third Bancorp
- $28.3 Billion
- Q2 2025
A detailed history of Fifth Third Bancorp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 3,300 shares of AKBA stock, worth $11,286. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,300
Previous 3,300
-0.0%
Holding current value
$11,286
Previous $6,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AKBA
# of Institutions
165Shares Held
96.7MCall Options Held
98.6KPut Options Held
320K-
Vanguard Group Inc Valley Forge, PA12.7MShares$43.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.8 Million0.0% of portfolio
-
State Street Corp Boston, MA6.81MShares$23.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$20.8 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$19.7 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $629M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...